These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 8772625

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine.
    Lau CP, Chow MS, Tse HF, Tang MO, Fan C.
    Am J Cardiol; 2000 Dec 15; 86(12):1327-32. PubMed ID: 11113407
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group.
    Aliot E, Denjoy I.
    Am J Cardiol; 1996 Jan 25; 77(3):66A-71A. PubMed ID: 8607394
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study.
    Kosior DA, Kochanowski J, Scisło P, Piatkowski R, Postuła M, Rabczenko D, Opolski G.
    Cardiol J; 2009 Jan 25; 16(6):521-7. PubMed ID: 19950088
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study.
    Capucci A, Villani GQ, Aschieri D, Piepoli M.
    Int J Cardiol; 1999 Feb 28; 68(2):187-96. PubMed ID: 10189007
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy.
    Pritchett EL, McCarthy EA, Wilkinson WE.
    Ann Intern Med; 1991 Apr 01; 114(7):539-44. PubMed ID: 2001087
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [A comparison between propafenone and hydroquinidine perorally in the treatment of recent-onset atrial fibrillation].
    Satullo G, Arrigo F, Cavallaro L, Coglitore A, Fazio F, Saporito F, Sorrenti S, Oreto G.
    Minerva Cardioangiol; 1996 Mar 01; 44(3):141-4. PubMed ID: 8767614
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators.
    Chimienti M, Cullen MT, Casadei G.
    Am J Cardiol; 1996 Jan 25; 77(3):60A-75A. PubMed ID: 8607393
    [Abstract] [Full Text] [Related]

  • 19. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group.
    Naccarelli GV, Dorian P, Hohnloser SH, Coumel P.
    Am J Cardiol; 1996 Jan 25; 77(3):53A-59A. PubMed ID: 8607392
    [Abstract] [Full Text] [Related]

  • 20. [Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study].
    Bellandi F, Dabizzi RP, Niccoli L, Cantini F, Palchetti R.
    G Ital Cardiol; 1996 Apr 25; 26(4):379-90. PubMed ID: 8707022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.